Eliquis for deep vein thrombosis treatment
What is DVT or deep vein thrombosis? DVT or deep vein thrombosis is a form of blood clot that is formed in the veins of the body. These blood clotted veins are usually on the lower part of the body, specifically on the thighs and lower legs. The condition wherein the veins are swelling is called thrombophlebitis. DVT can lead to a serious problem in the lung which is called pulmonary embolism. Venous thrombosis which may include DVT (deep vein thrombosis) and pulmonary embolism usually occurs to men more than women who at the age of 45 and up.
Other risk factors for this type of disease are immobility, trauma, hospitalization, surgery, obesity and many more. There is also the factor of it being inherited and acquired disorders of hypercoagulation. Many doctors believe that the complete understanding of venous thrombosis or DVT is needed so as to prevent this type of high-risk disease.
What are the known treatments for DVT?
The development of a Pulmonary Embolus is the main target of DVT(deep vein thrombosis). Doctors usually use anti-coagulant medications which are primarily used for blood thinning as a treatment for deep vein thrombosis. One of the most effective and doctor-prescribed medication for DVT is Eliquis, which is the trade name for Apixaban. Elequis drug has been approved for the treatment for deep vein thrombosis since 2014. Some low dosage of Eliquis drug can also be used in preventing lung embolism.
The body breaks down blood clotting at a high rate that it usually does not cause any symptoms, but this blood clot can still cause a vein clogging somewhere else in the body. For the deep vein thrombosis treatment, Eliquis is the right drug for the job.
Bristol-Myers Squibb is a global biopharmaceutical company that is behind the production of the drug Eliquis. This pharmaceutical company is headquartered in New York City, in the United States. It has been founded in the year 1887. Among the other diseases that they specialize in making prescription drugs are cancer, HIV/AIDS, hepatitis, diabetes, rheumatoid arthritis, and cardiovascular disease.
What are the dosages for Eliquis?
This is a prescription medicine which means that you cannot just buy it without a doctor’s prescription. Listed below are the doctor-prescribed dosages for Eliquis.
Eliquis has two types of tablets:
- A 2.5mg tablet Eliquis which is primarily for patients that have either of the 2 characteristics:
Age > 80 years
Body weight of < 60 kg
Serum creatinine level > 1.5 mg per dL (133 ol per L)
- A 5mg tablets Eliquis for patients that are not under the characteristics indicated above.
5mg tablets can be taken with or without food in the stomach of the patient, taken twice daily in most patients which has the indication of the reduction of stroke risk or systemic embolism in NVAF or Nonvalvular Atrial Fibrillation.
2.5mg Eliquis tablet is taken twice daily after at least 6 months of DVT (deep vein thrombosis) or PE treatment.
This dosage instruction is of generally prescribed. For other proper prescription, please do not hesitate to consult your doctor.
What are the safety implications of Eliquis?
Eliquis is better than warfarin in terms of the lower risk of bleeding, although compared to aspirin; it has a higher risk of minor bleeding. Warfarin treatment has a higher risk of death than being medicated with Apixaban. With the discontinuation of Eliquis treatment places the patient at a higher risk of thrombotic events. Excused discontinuation of treatment can be because of serious bleeding, which means patients can be prescribed with another anti-coagulant medication to prevent the higher risk of having a stroke.
The co-administration of Eliquis with other antiplatelet agents, chronic non-steroidal anti-inflammatory drugs along with others increases the risk of bleeding. Children, pregnant or breastfeeding women have not been part of the study research for Eliquis.
How effective is Eliquis?
Eliquis has a similarity with other stroke prevention medicine in the market today. Eliquis has not been linked to other anti-coagulant medicine such as Dabigatran, and Rivaroxaban. Systemic embolism was also proven to have been lower with the prescribed use of Eliquis. In addition to this, the number of death recorded annually and its cause was not directly linked that were insignificant to patients taking Eliquis or aspirin.
Eliquis, statistically speaking, is as effective as aspirin and warfarin in the prevention of strokes in patients that have nonvalvular atrial fibrillation, especially those who elect not to take warfarin. It is unlikely to cause any bleeding as it is guaranteed in compliance with FDA regulations and does not need frequent monitoring by the laboratory. However, Eliquis is more expensive than warfarin or aspirin, and it is irreversible anti-coagulation process especially during emergency cases.